TEVA Stock Recent News

Teva Pharmaceuticals Industries Limited (NYSE:TEVA ) Bank of America Global Healthcare Conference September 18, 2024 3:15 AM ET Company Participants Richard Francis - President & CEO Conference Call Participants Jason Gerberry - BofA Securities Jason Gerberry Thank you, Richard, for joining us here at the BofA Global Healthcare Conference in London. My name is Jason Gerberry.

Baltimore said on Tuesday that it has settled with Walgreens over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.

MONTPELLIER, France--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced during the 22nd Annual Global Healthcare Conference held yesterday that c.99% of the targeted injections for submission have been performed as of today (replay available here). Teva also confirmed that the full submission safety results are expected to be available in H2 24. Olanzapine LAI is an investigational once-monthly subcutaneous long-acting.

Step by step, Teva's management is making progress in transforming it from a generic drugmaker into one that will play a key role in the fight against immune-related disorders. Its revenue was about $4.16 billion in the second quarter of 2024, up 7.2% year-on-year. So, in addition to the growth in sales of its generic products, there is also increased demand for innovative medications, including Austedo and Uzedy.

TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook.

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Richard Francis - President & CEO Eli Kalif - CFO Eric Hughes - Head, R&D & Chief Medical Officer Ran Meir - SVP, head of IR Conference Call Participants Ash Verma - UBS Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Omri Efroni - Oppenheimer Umer Raffat - Evercore Glen Santangelo - Jefferies Chris Schott - J.P. Morgan Yifeng Liu - HSBC Operator Hello, and welcome to the Teva Pharmaceuticals Industries Limited Q2 2024 Earnings Call.

Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss how much of the company's momentum is around its generic obesity drug, the market's excitement around its GLP-1 drug, and much more.

Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.